UMnyango Wezizwe Zonke

Ngomhlaka-20 Agasti 2025, i-Abbisko Therapeutics yamemezela ukuthi i-Center forDrug Evaluation (CDE) ye-China National Medical Products Administration (NlPA) isivumile isicelo se-lND somuthi womlomo we-Abbisko ophenywayo we-PD-1, i-ABSK043, ohlanganiswe ne-Shanghai Alist Pharmaceuticals KRAS ...Funda kabanzi»

Muva nje, ucwaningo lwe-Antengene's Phase I/II CLINCH lwe-ATG-022 (i-CLDN18.2 antibody-drug conjugate), isiguli esikhulile esinomdlavuza wesisu othuthukile esiye sathuthuka emigqeni eminingi ye-chemotherapy, i-immunotherapy kanye nokwelashwa okuqondisiwe naphezu kokukhula kwe-metastases ebanzi, sithole impendulo ephelele (CR) ngokulandelayo...Funda kabanzi»

Ngo-Agasti 13, 2025, i-Pacific Time, iwebhusayithi esemthethweni yeNgqungquthela Yomhlaba Yomdlavuza Wamaphaphu ka-2025 (WCLC) ikhiphe izifinyezo zocwaningo ezikhethiwe zengqungquthela yalo nyaka, Phakathi kwezinto ezivelele kukhona isifinyezo esibuyekeziwe sesilingo sokuqala somtholampilo seSigaba 1 se-HLX43, i-Henlius' PD-L1 ADC. A...Funda kabanzi»

Ngomhlaka-7 Agasti, i-Center for Drug Evaluation (CDE) ye-National Medical Products Administration (NMPA) yamemezela ukuthi umjovo we-PA3-17 uphakanyiswe ukuthi ufakwe ekwakhiweni kokwelashwa okuphumelelayo, okuhloswe ekwelapheni iziguli ezindala ezine-lymph ephindaphindayo/engaphenduli kahle ye-T-cell...Funda kabanzi»

Ngomhlaka-11 Agasti, i-Center for Drug Evaluation (CDE) ye-National Medical Products Administration (NMPA) iveze ukuthi isicelo se-InxMed samaphilisi e-IN10018 siphakanyisiwe ukuze kunqunywe ukwelashwa okuphumelelayo, okuhloswe ukuhlanganiswa ne-D-1553 ukwelapha i-KRA ethuthukisiwe noma esakazeke endaweni...Funda kabanzi»

UMnu. X uyisiguli esiseminyakeni yakhe yo-40 esitholakale sine-acral melanoma. Ngemva kokuhlinzwa okukhulu ngemuva kokuxilongwa kwakhe ngo-2015, isimo sakhe sahlala sizinzile iminyaka eyisishiyagalolunye. Ngeshwa, cishe ngonyaka odlule, lesi sifo saphinde savela ngama-metastases emaphashini womabili. Naphezu kokuthola i-inguinal kanye ne-pelvic l...Funda kabanzi»

Ngomhlaka-31 kuNtulikazi, i-AstraZeneca kanye ne-Merck & Co. bamemezele ngokuhlanganyela ukuthi umuthi wabo we-PARP inhibitor uLynparza, kanye ne-Abiraterone kanye ne-prednisolone, usuvunyelwe eShayina ekwelapheni iziguli ezindala ezinomdlavuza we-prostate omelana nomdlavuza we-metastatic castration (mCRPC) ezinegciwane noma ezinye izinhlobo zegciwane...Funda kabanzi»

Ngomhlaka-31 kuNtulikazi 2025, i-ImmuneOnco Biopharmaceuticals imemezele idatha yokuqala yokuphepha nokusebenza kahle evela ocwaningweni lwe-IMM2510 oluvulekile lwesigaba sesi-2 oluhlanganisa izikhungo eziningi kanye ne-chemotherapy yeziguli ezisebenza phambili ezinomdlavuza wamaphaphu ongewona omncane (i-NSCLC) oqhutshwe eShayina. Kusukela ngomhlaka-1 kuNtulikazi 2025,...Funda kabanzi»

Ngomhlaka-30 kuJulayi, i-National Medical Products Administration (NMPA) yagunyaza ngokusemthethweni ukumaketha kwe-HICARA ekwelapheni iziguli ezindala ezine-lymphoma enkulu ye-B-cell ephinde yabuya noma engaphikisi (r/r LBCL) ezithole imigqa emibili noma ngaphezulu yokwelashwa kwesistimu. Lokhu kufaka phakathi i-diffuse large B-cell ...Funda kabanzi»

Muva nje, isiguli esinomdlavuza we-pancreatic othuthukile esasihlulekile emigqeni eminingi yokwelashwa ngaphambilini sathola ukuncishiswa kwesimila ngemuva kokuthola ukwelashwa kweseli le-KD-496 CAR-T, kanti ukukhululeka okuqinisekisiwe kugcinwe ezinsukwini ezingu-180 ngemuva kokwelashwa. Okwamanje, kusenezivivinyo eziningi zemitholampilo zesifo esisha...Funda kabanzi»

Ngomhlaka-16 kuJulayi, iphephabhuku lomhlaba wonke elihamba phambili i-Nature Medicine lashicilela idatha yocwaningo nge-SHR-A1904, i-antibody-drug conjugate (ADC) ehlose i-claudin 18.2 (CLDN18.2), yokwelapha umdlavuza wesisu osezingeni eliphezulu noma umdlavuza we-gastroesophageal junction (GC/GEJC). Abacwaningi benze ucwaningo lokuqala...Funda kabanzi»

Julayi 17, 2025 - I-Innovent Biologics imemezele ukuthi i-Nature Medicine ishicilele imiphumela yocwaningo lwezokwelapha lweSigaba 1 lwe-IBI343, i-anti-CLDN18.2 ADC entsha, yokwelapha i-advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Ukushicilelwa kule nhlangano ehamba phambili yamazwe ngamazwe...Funda kabanzi»